Multiplesclerosis(MS)isachronic,inflammatory,immune-mediateddiseaseof the central nervous system (CNS). More than 2 million people worldwidehave MS. The goal of the present study was to compare Iraqi patients' treat-ment satisfaction with three different disease-modifying therapies (DMTs),administeredorally,subcutaneously,andbyslowinfusion;namely,fin-golimod, interferon beta-1b (IFNβ-1b), and natalizumab, respectively. Aswell as to assess the individual differences among these therapies about theireffectiveness, convenience and global satisfaction also to assess the role ofcertain predictors on treatment satisfaction. Patient satisfaction with medi-cation assessed by the Treatment Satisfaction Questionnaire for Medication(TSQM-9) which comprises three components medication effectiveness, con-venience, and global satisfaction. For The treatment satisfaction outcomes,the IFNβ-1b using patients had the lowest score forall TSQM-9 subscales. Themost consistent differences among the groups were related to the conven-ienceofthemedication,withoralfingolimodhavethehighestscoresandna-talizumab the second. Regarding global satisfaction, natalizumab using groupreported significantly higher satisfaction, as compared to both IFNβ-1b andfingolimod using groups. In conclusion, Iraqi relapsing-remitting MS patientsare more satisfied with the natalizumab than with IFNβ-1b or fingolimod.Some predictors such as age, EDSS and duration of treatment, correlate withthelevel of satisfactionwithdifferent treatments